MPM BioImpact LLC WVE — Wave Life Sciences PTE LTD

Ownership history in MPM BioImpact LLC  ·  5 quarters on record

AI Ownership Summary

MPM BioImpact LLC reported Wave Life Sciences PTE LTD (WVE) in 5 quarterly 13F filings from 2024 Q3 through 2025 Q3. Peak portfolio weight reached 2.62% in 2024 Q4. The latest visible filing shows WVE at 1.80% of the fund.

This page tracks quarterly shares, estimated market value, portfolio weight, filing dates, and disclosure-aligned stock prices directly from SEC EDGAR 13F filings.

What this WVE ownership page tells you

This page is designed to answer the real investor question behind a 13F filing: how meaningful was MPM BioImpact LLC's position in Wave Life Sciences PTE LTD, and how did that conviction change over time? You can read the holding window, peak weight, latest reported size, disclosure timing, and quarter-by-quarter changes without piecing the story together from raw SEC rows.

Freshest filing
Latest Reported Filing
2025 Q3

WVE was reported at 1.80% of portfolio in the most recent visible filing.

High-water mark
Peak Conviction
2.62% in 2024 Q4

Peak weight helps separate a token disclosure from a real conviction holding the fund genuinely cared about.

Time in book
Holding Window
2024 Q3 to 2025 Q3

Longer holding windows often tell a very different story from short-lived tactical trades or one-quarter experiments.

Decision context
Why It Matters
Position size beats headlines

Knowing that a fund owned a stock is useful. Knowing whether it was a 0.20% placeholder or a true high-conviction position is where the signal actually starts.

WVE stock page MPM BioImpact LLC fund profile MPM BioImpact LLC full holdings
How MPM BioImpact LLC held WVE — position size vs. price
% of Fund (quarterly)    WVE price (quarter-end, indexed to 100)    SPY (indexed to 100)    QQQ (indexed to 100)
📋 Quarterly Holdings History 5 quarters  ▾
Quarter Action Sold % After 3M Timing Shares Change Chg % % of Fund Mkt Value Filed Price (Filed)
2025 Q3 UNCHANGED — — — 1,505,262 — 0% 1.80% $11.0M 2025-11-14 $7.08
2025 Q2 REDUCED — — — 1,505,262 -4,318 -0.3% 1.70% $9.8M 2025-08-14 $8.91
2025 Q1 ADDED — — — 1,509,580 +20,343 +1.4% 2.10% $12.2M 2025-05-15 $6.30
2024 Q4 ADDED — — — 1,489,237 +864,766 +138.5% 2.62% $18.4M 2025-02-14 $10.81
2024 Q3 INITIATED — — — 624,471 — — 0.77% $5.1M 2024-11-13 $15.69

🏢 Other funds also holding WVE

As of 2026 Q1 — sorted by position size

Capstone Capital Management Ltd 1.05% Privium Fund Management B.V. 3Y 0.36% MOODY ALDRICH PARTNERS LLC 3Y 7Y 0.36% EMERALD ADVISERS, LLC 3Y 7Y 0.29% EMERALD MUTUAL FUND ADVISERS TRUST 3Y 7Y 0.29% AlphaCentric Advisors LLC 3Y 0.21% James J. Burns & Company, LLC 3Y 0.11% Y-Intercept (Hong Kong) Ltd 3Y 0.02% China Universal Asset Management Co., Ltd. 3Y 0.02% NJ State Employees Deferred Compensation Plan 3Y 7Y 0.01%

FAQ About MPM BioImpact LLC and WVE

These are the practical questions this page is built to answer before you even open the full history table.

How long has MPM BioImpact LLC reported owning WVE?

MPM BioImpact LLC reported WVE across 5 quarterly 13F filings, from 2024 Q3 through 2025 Q3.

What was the largest reported WVE position in MPM BioImpact LLC's portfolio?

The largest reported portfolio weight for WVE was 2.62% in 2024 Q4.

What is the latest reported WVE position on this page?

The most recent filing on this page is 2025 Q3, when MPM BioImpact LLC reported 1,505,262 shares, equal to 1.80% of portfolio, with an estimated market value of $11.0M.

What does the chart on this WVE ownership page compare?

The chart compares MPM BioImpact LLC's quarterly WVE portfolio weight with the stock's indexed share price, so you can see whether the fund was building, trimming, or holding the position as price moved.

How well did MPM BioImpact LLC time their WVE position?

Based on 13F filing dates vs. subsequent WVE price moves, MPM BioImpact LLC correctly timed 2 out of 4 reported position changes (50%). The annualised alpha on WVE relative to SPY over the holding period was -60.3%.

← Back to MPM BioImpact LLC Holdings